Filter Specialty
Filterspecialty
Submit To The Journals
Previous
Article
Next
Article

How to Identify Retinoblastoma in Pediatric Patients

US Ophthalmic Review. 2018;11(2):77–8 DOI: https://doi.org/10.17925/USOR.2018.11.2.77

Abstract

Retinoblastoma is the most common primary intraocular tumor in pediatric patients. The incidence accounts for 1 in 20,000 live births. With the improvement of treatment alternatives the survival rate of these patients has improved in recent years, with up to 95% survival in the US. The use of multimodal investigations including ultrasonography, computed tomography, magnetic resonance imaging, and wide-field fundus photography with intravenous fluorescein angiography is crucial to identify retinoblastoma in pediatric patients.

Keywords

Retinoblastoma identification, pediatric patients, ocular imaging

Disclosure

Supalert Prakhunhungsit and Audina M Berrocal have nothing to disclose in relation to this article.

Review Process

This article is a short opinion piece and has not been submitted to external peer reviewers but was reviewed by the editorial board for accuracy before publication.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Open Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. © The Author 2018.

Received

June 05, 2018

Published Online

October 15, 2018

Correspondence

Audina M Berrocal, Retina Department, Bascom Palmer Eye Institute, 900 NW 17th street, Miami, FL 33136, US. E: aberrocal@med.miami.edu

Support

No funding was received in the publication of this article.

One of the most important differential diagnoses in the pediatric retina population is retinoblastoma. A detailed history, good eye examination, good ultrasonography, and any other ancillary tests are essential for making the correct diagnosis.

Retinoblastoma is the most common primary ocular tumor in pediatric patients. The incidence accounts for 1 in 20,000 live births and approximately 300 new cases per year in the US.1 Two-thirds of cases were diagnosed before the age of 2 years and it is rare for the diagnosis to present after5 years of age.1 The improvement of treatment strategies evolving from enucleation or external beam radiation to more advanced globe-saving therapies in recent years has increased the survival rate of children with retinoblastoma to more than 95% in developed countries.2

The clinical pearls to identify the pediatric patients with retinoblastoma should start from a detailed medical history and a complete physical examination. The family history of retinoblastoma or other malignancies should be scrutinized, not only for an accurate diagnosis, but also to advise families. Genetic testing and genetic counseling is of utmost importance. A careful ocular examination, usually under general anesthesia, should be conducted to assess the intraocular findings and ascertain which layer of the retina is involved: preretinal, intraretinal, or subretinal layers. This will help in understanding what kind of tumor presentation we are dealing with.

B-scan ultrasonography

A B-scan ultrasonography of the tumor offers important information, but it is not always perfect. The heterogeneity and calcification detection within the intraocular mass from ultrasonography provide strong evidence for the diagnosis of retinoblastoma. Specifically, calcium within an intraocular mass in children before the age of 3 years is highly suspicious for retinoblastoma until proven otherwise. Although histopathological examination of enucleated globes showed approximately 95% of calcium deposit within the tumor,3 the ocular ultrasonography is not as sensitive as other advanced imaging modalities to detect the calcification.4 Echography can also detect subretinal fluid or seeding, tumor growth patterns, and in some circumstances, vitreous seeding.5

Computed tomography scan and magnetic resonance imaging

Most of the time, other imaging modalities such as computed tomography (CT) scan or magnetic resonance imaging (MRI), are needed. Moreover, CT scans and MRI can detect the extraocular extension and intracranial lesions in patients with trilateral disease, which leads to accurate disease staging and appropriate treatment thereafter. CT scans are one of the most effective methods of detecting calcification, but with the concern of radiation exposure in patients with retinoblastoma with germline mutation, it is generally avoided.6 The benefit of MRI over CT is the detection of the optic nerve invasion which is one of the prognostic factors in retinoblastoma. Furthermore, MRI is also superior to CT in terms of soft tissue delineation to uncover pineal tumors in trilateral retinoblastoma cases or, rarely, in the suprasellar region or leptomeningeal spread.7 However, MRI is less sensitive to detect intralesional calcification than CT.

Wide-field fundus photography with intravenous fluorescein angiography

Wide-field fundus photography with intravenous fluorescein angiography (IVFA) in the operating room is helpful in making a diagnosis, especially in cases with unusual presentation. Advanced endophytic or exophytic retinoblastoma is often associated with large vessel tortuosity and dilatation with small vessel telangiectasia and microaneurysm, intrinsic tumor vasculature and late leakage in IVFA photographs.8 On the other hand in the diffuse retinoblastoma it becomes more challenging to make the diagnosis. In these cases, IVFA demonstrates complex branching with tortuosity and telangiectatic vessels within the area of the mass. The feeder vessels show early termination and are variably visualized as a consequence of the overlying tumor.9 Furthermore, IVFA is also useful in differentiating retinoblastoma from Coats’ disease, a common confounding entity. Retinoblastoma does not present telangiectatic vasculature with aneurysmal dilatation as it would in patients with Coats’ disease. IVFA is also capable of distinguishing retinoblastoma cases with Coats’-like response from Coats’ disease. The anterior segment fluorescein angiograms, derived from IVFA, capturing the iris vasculature detail, is also worthwhile in guiding the diagnosis of advanced retinoblastoma. Iris neovascularization, present in advanced disease, will be enhanced by injected dye and consequently the extension of the disease in group E retinoblastoma can be detected. Additionally, the IVFA in the fellow eye also provides useful information for making a complete diagnosis in peculiar cases. The area of peripheral retinal avascularity in the other eye could point to familial exudative vitreoretinopathy (FEVR). In pediatric patients with a history of prematurity and vitreous hemorrhage, the IVFA findings in the other eye aid in making the correct diagnosis. Pruning of the vasculature with budding into the area of retinal nonperfusion could lead to the diagnosis of retinopathy of prematurity with FEVR.10 Recognition of atypical characteristics, i.e., older age, unilateral cases, and atypical color, is always advantageous to the critical use of wide-field photography with IVFA and diagnostic echography.

Once retinoblastoma is suspected, intravitreal injection and any intraocular surgeries should be strictly avoided as they can cause orbital extension.11 When intraocular surgery is performed in cases with atypical presentation, the aqueous, vitreous, or any removed tissue should be sent for histopathological examination. When in doubt of the diagnosis of retinoblastoma, a referral and consultation for a second opinion from a pediatric ocular oncologist is definitely a reasonable and recommended option.

Conclusion

As a pediatric retina specialist, the best advice in the diagnosis of atypical retinoblastoma is to THINK about it. If it is unusual, if it doesn’t make sense to you STOP. Do more testing and if you cannot be sure then send the case to a pediatric ocular oncologist. Additionally, always look carefully at the other eye.

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchOphthalmology is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.